How Biotech Startups Use Protein Degradation to Drug the Undruggable

Episode 47 of Biotech Business with Fexingo dives into targeted protein degradation — a drug discovery approach that destroys disease-causing proteins rather than inhibiting them. Lucas and Luna unpack how startups like Arvinas and Kymera are leveraging the cell's own garbage disposal, the proteasome, to tackle targets previously considered undruggable. They discuss the first FDA approval of a PROTAC drug in 2025, what it means for the industry, and the specific design challenges — from ternary complex formation to oral bioavailability. This episode includes a brief, sincere pitch for listener support to keep the show ad-free. #TargetedProteinDegradation #PROTACs #Arvinas #KymeraTherapeutics #Undruggable #DrugDiscovery #BiotechStartup #Proteasome #FDAApproval #MolecularGlue #TernaryComplex #OralBioavailability #LifeSciences #BusinessAndTechnology #FexingoBusiness #BusinessPodcast #Biotech #StartupFunding Keep every episode free: buymeacoffee.com/fexingo